Company Overview

Scorpius Holdings, Inc. is a U.S.-based biotechnology and pharmaceutical services company operating in the life sciences, biologics manufacturing, and contract development and manufacturing organization (CDMO) industries. The company’s activities span biologics development, advanced pharmaceutical manufacturing services, and technology-enabled solutions supporting drug developers. Its primary revenue drivers are centered on fee-for-service manufacturing, development services, and ancillary technology platforms designed to support biopharmaceutical production.

Formerly known as Heat Biologics, Inc., the company historically focused on immuno-oncology and vaccine development before undertaking a strategic transformation. Beginning in 2022–2023, Scorpius shifted away from internal drug discovery toward building an integrated biologics services platform. This evolution was driven by acquisitions and internal restructuring aimed at addressing growing demand for flexible, domestic biologics manufacturing capacity, particularly among small and mid-sized biotechnology companies.

Business Operations

Scorpius Holdings conducts operations primarily through its biologics manufacturing and pharmaceutical services subsidiaries, with Scorpius Biomanufacturing, Inc. serving as its core operating unit. This business focuses on microbial and mammalian cell-based biologics manufacturing, analytical testing, process development, and scale-up services. Revenue is generated through long-term and project-based service contracts with biopharmaceutical clients.

The company’s operations are predominantly domestic, with facilities and service delivery concentrated in the United States. Scorpius controls manufacturing assets, laboratory infrastructure, and proprietary process know-how that support end-to-end biologics development. Public disclosures indicate that while the company engages with commercial partners and clients, material joint ventures or revenue-dependent strategic partnerships have not been consistently disclosed, and details on customer concentration remain limited in public filings.

Strategic Position & Investments

Scorpius Holdings’ strategic direction emphasizes becoming an integrated, U.S.-based biologics CDMO with a focus on flexibility, speed, and support for emerging biotechnology companies. Growth initiatives include expanding manufacturing capacity, improving operational efficiency, and cross-selling development and manufacturing services across its client base. The company has stated an intention to pursue selective acquisitions that enhance technical capabilities or expand service offerings.

A key strategic investment was the acquisition and build-out of Scorpius Biomanufacturing, Inc., which represents the company’s primary operating and revenue-generating subsidiary. The company has also highlighted interest in advanced biologics modalities and manufacturing technologies, though specific commercial-stage technology investments beyond its core CDMO platform are not comprehensively detailed. Data inconclusive based on available public sources regarding the scale and timing of future acquisitions.

Geographic Footprint

Scorpius Holdings is headquartered in the United States, with its principal operations and manufacturing infrastructure located in North America. The company’s facilities are designed to serve domestic biotechnology and pharmaceutical customers, with an emphasis on U.S.-based production to meet regulatory, supply chain, and national security considerations.

While the company markets its services to international clients, its operational footprint outside the United States is limited based on publicly available disclosures. There is no confirmed evidence of owned manufacturing facilities in Europe, Asia-Pacific, or other regions, though the company may support international customers through U.S.-based operations.

Leadership & Governance

Scorpius Holdings is led by executives with backgrounds in biotechnology, manufacturing operations, and corporate restructuring. Leadership has emphasized capital discipline, operational execution, and transitioning the company toward sustainable service-based revenues following its strategic pivot from drug development.

Key executives include:

• Jeffrey S. Wolf – President and Chief Executive Officer
• John R. Stetson – Chief Financial Officer
• Michael R. Catelani – Chief Operating Officer
• Robert J. Johnson – Chief Legal and Compliance Officer

The leadership team’s stated strategic vision focuses on building scalable biologics manufacturing capabilities while reducing reliance on high-risk internal R&D programs. Governance practices are aligned with U.S. public company standards, as reflected in periodic disclosures and filings with the U.S. Securities and Exchange Commission (SEC).